What's the place of immunotherapy in malignant mesothelioma treatments?

We recently investigated on the in vitro effect of a sequential treatment of mesothelioma cells with DNA methyl transferase and histone de-acetylase inhibitors, and demonstrated the expression of cancer testis antigens such as the New-York esophageal cancer and the melanoma-associated antigen

Marc Grégoire

2010

Scholarcy highlights

  • Malignant mesothelioma are cancers affecting serous membranes, more than 80% of which affect the pleura
  • Treatments evaluated for malignant mesothelioma, including chemotherapy, radiotherapy and surgery are of limited efficacy
  • In the case of Malignant pleural mesothelioma, several clinical studies have demonstrated a correlation between the presence of a lymphocyte infiltrate and a better prognosis and humoral response directed against specific antigens related to tumor
  • Radiotherapy and certain chemotherapies drugs can induce death in a large number of cells that could thereafter release tumor antigens. These antigens can be taken up by antigen presenting cells, such as dendritic cells. These tumor antigen-loaded cells can activate an immune response that can be further sensitized by a therapeutic vaccination
  • The selection of patients is of utmost importance for anti-tumor efficacy. This is because the adjuvant therapeutic vaccination based on the injection of immune cells is more efficient when performed at an early stage, as previously demonstrated for melanoma
  • As a complement to this type of strategy and in order to increase efficacy, recent data from previous clinical trials suggest the utility of targeting and inactivating the regulatory T cell population. If one takes these different results into account i.e., the observations concerning the immune populations in patients suffering from mesothelioma and the ease of access to the local tumor site within the pleural cavity, this pathology should be the subject of several cellular immunotherapy trials in the near future
  • This is because the adjuvant therapeutic vaccination based on the injection of immune cells is more efficient when performed at an early stage, as previously demonstrated for melanoma. As a complement to this type of strategy and in order to increase efficacy, recent data from previous clinical trials suggest the utility of targeting and inactivating the regulatory T cell population. For this reason, if one takes these different results into account i.e., the observations concerning the immune populations in patients suffering from mesothelioma and the ease of access to the local tumor site within the pleural cavity, this pathology should be the subject of several cellular immunotherapy trials in the near future

Need more features? Save interactive summary cards to your Scholarcy Library.